| pubmed-article:3860688 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3860688 | lifeskim:mentions | umls-concept:C0003392 | lld:lifeskim |
| pubmed-article:3860688 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:3860688 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:3860688 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3860688 | pubmed:dateCreated | 1985-9-5 | lld:pubmed |
| pubmed-article:3860688 | pubmed:abstractText | Proline analogues such as cis-4-hydroxy-L-proline (CHP) and L-azetidine-2-carboxylic acid (A2C) were tested for their antitumor activity in tissue culture and in vivo. In culture, CHP specifically inhibited those tumor cells that synthesized basement-membrane collagen. CHP appeared to selectively inhibit collagen biosynthesis with only a slight effect on protein synthesis. Culturing cells on type IV collagen matrix did not alter the antiproliferative effect of CHP. The inhibition of 450.1 mouse mammary tumor cells was fully reversible when cultures were incubated for 6 or 12 hours with 25 micrograms CHP/ml but was irreversible after 24 hours of exposure. Of the proline analogues tested against 450.1 tumor cells, A2C and CHP were the most potent inhibitors of cell growth. These two compounds were therefore tested in vivo using 3 transplantable tumors, all of which synthesized basement-membrane collagen. CHP and A2C were given twice daily to mice for 7 to 10 days at doses ranging from 50 mg/kg (body wt) to 600 mg/kg (body wt) per injection. Both CHP and A2C were completely inactive against the 450.1 mammary tumor and the EHS sarcoma. Both compounds also caused considerable liver toxicity. Against CD8F1 mammary tumors, treatment with maximum tolerated doses of CHP and A2C resulted in a slight but insignificant inhibition of tumor growth. While our studies confirmed previous findings that CHP specifically inhibited those tumor cells that synthesized basement-membrane collagen, CHP and A2C did not appear to be efficacious antitumor agents. | lld:pubmed |
| pubmed-article:3860688 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3860688 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3860688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3860688 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3860688 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3860688 | pubmed:issn | 0027-8874 | lld:pubmed |
| pubmed-article:3860688 | pubmed:author | pubmed-author:WichaM SMS | lld:pubmed |
| pubmed-article:3860688 | pubmed:author | pubmed-author:KlohsW DWD | lld:pubmed |
| pubmed-article:3860688 | pubmed:author | pubmed-author:LeopoldW RWR | lld:pubmed |
| pubmed-article:3860688 | pubmed:author | pubmed-author:TunacJ BJB | lld:pubmed |
| pubmed-article:3860688 | pubmed:author | pubmed-author:SteinkampfR... | lld:pubmed |
| pubmed-article:3860688 | pubmed:author | pubmed-author:MertusA EAE | lld:pubmed |
| pubmed-article:3860688 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3860688 | pubmed:volume | 75 | lld:pubmed |
| pubmed-article:3860688 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3860688 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3860688 | pubmed:pagination | 353-9 | lld:pubmed |
| pubmed-article:3860688 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:meshHeading | pubmed-meshheading:3860688-... | lld:pubmed |
| pubmed-article:3860688 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3860688 | pubmed:articleTitle | Collagen-production inhibitors evaluated as antitumor agents. | lld:pubmed |
| pubmed-article:3860688 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3860688 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
